Human tumor cells are selectively inhibited by colicins
Jazyk angličtina Země Spojené státy americké Médium print
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
12744087
DOI
10.1007/bf02931286
Knihovny.cz E-zdroje
- MeSH
- buněčný cyklus účinky léků MeSH
- eukaryotické buňky účinky léků MeSH
- fibroblasty účinky léků MeSH
- G1 fáze účinky léků MeSH
- koliciny farmakologie MeSH
- lidé MeSH
- mutace MeSH
- nádorové buňky kultivované účinky léků MeSH
- nádorový supresorový protein p53 genetika MeSH
- tetrazoliové soli metabolismus MeSH
- thiazoly metabolismus MeSH
- viabilita buněk účinky léků MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- koliciny MeSH
- nádorový supresorový protein p53 MeSH
- tetrazoliové soli MeSH
- thiazoly MeSH
- thiazolyl blue MeSH Prohlížeč
The activity in vitro of four types of colicins (A, E1, E3, U) against one human standard fibroblast line and against 11 human tumor-cell lines carrying defined mutations of the p53 gene was quantified by MTT (tetrazolium bromide) assay. Flow cytometry showed that the pore-forming colicins A, E1 and U affected the cell cycle of 5 of these cell lines. Colicins E3 and U did not show any distinct inhibitory effects on the cell lines, while colicins E1 and especially A inhibited the growth of all of them (with one exception concerning colicin E1). Colicin E1 inhibited the growth of the tumor lines by 17-40% and standard fibroblasts MRC5 by 11%. Colicin A exhibited a differentiated 16-56% inhibition, the growth of standard fibroblasts being inhibited by 36%. In three of the lines, colicins A and E1 increased the number of cells in the G1 phase (by 12-58%) and in apoptosis (by 7-58%). These results correlated with the data from sensitivity assays. Hence, the inhibitory effect of colicins on eukaryotic cells in cell-selective, colicin-specific and can be considered to be cytotoxic.
Zobrazit více v PubMed
Folia Microbiol (Praha). 2002;47(3):213-7 PubMed
Vet Pathol. 1998 Nov;35(6):461-78 PubMed
Z Allg Mikrobiol. 1979;19(7):511-6 PubMed
Folia Microbiol (Praha). 2001;46(1):49-52 PubMed
Cancer Res. 1979 Dec;39(12):5114-7 PubMed
Eur J Cancer Clin Oncol. 1987 Apr;23(4):411-8 PubMed
Cell Mol Biol. 1986;32(5):607-17 PubMed
Folia Biol (Praha). 2001;47(1):11-3 PubMed
Cell. 1997 Feb 7;88(3):323-31 PubMed
Folia Microbiol (Praha). 2000;45(5):379-85 PubMed
Int J Cancer. 1998 Sep 11;77(6):913-8 PubMed
Folia Microbiol (Praha). 1978;23(4):272-7 PubMed
Cancer Res. 1976 Oct;36(10):3561-7 PubMed
J Cell Biochem Suppl. 1998;30-31:50-4 PubMed
Folia Microbiol (Praha). 2001;46(1):61-2 PubMed
Folia Microbiol (Praha). 1998;43(6):563-82 PubMed
Bacteriocin production by mucosal bacteria in current and previous colorectal neoplasia
Bacteriocinogeny in experimental pigs treated with indomethacin and Escherichia coli Nissle
